Dae‐Hyun Yoo

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Dae‐Hyun Yoo, Paweł Hrycaj, Pedro C. Miranda et al. · Annals of the Rheumatic Diseases · 2013 · 650 citations · Full text

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Won Park, Paweł Hrycaj, Volodymyr Kovalenko et al. · Annals of the Rheumatic Diseases · 2013 · 601 citations · Full text

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 479 citations

Rheumatoid Disorder, Rheumatology, Tofacitinib Monotherapy +8

CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway.

Elaine J. Schattner, K B Elkon, Dae‐Hyun Yoo et al. · The Journal of Experimental Medicine · 1995 · 283 citations · Full text

Inflammation, Cd40 Antigen, Medicine +14

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Dae‐Hyun Yoo, Nenad Prodanović, Janusz Jaworski et al. · Annals of the Rheumatic Diseases · 2016 · 278 citations · Full text